MiRNA, a New Treatment Strategy for Pulmonary Fibrosis

Abstract excerpt

Pulmonary fibrosis (PF) is the most common chronic, progressive interstitial lung disease, mainly occurring in the elderly, with a median survival of 2-4 years after diagnosis. Its high mortality rate attributes to the delay in diagnosis due to its generic symptoms, and more importantly, to the lack of effective treatments. MicroRNAs (miRNAs) are a class of small non-coding RNAs that are involved in many...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
• Share to Medical Imaging and Pathology Studies
• Share to Neonatal Respiratory Health Research